You are here

  • Home
  • Online First
  • Diagnosis and management of hidradenitis suppurativa: a review for the emergency clinician

Article Text

Article menu
Download PDFPDF
Practice review
Diagnosis and management of hidradenitis suppurativa: a review for the emergency clinician
  1. Daniel M Klufas1,
  2. Feyisayo Ojute2,
  3. Guy Shochat3,
  4. Haley B Naik1
  1. 1Dermatology, University of California San Francisco, San Francisco, California, USA
  2. 2School of Medicine, University of California San Francisco, San Francisco, California, USA
  3. 3Emergency Medicine, University of California San Francisco, San Francisco, California, USA
  1. Correspondence to Dr Daniel M Klufas; daniel.klufas{at}ucsf.edu

Abstract

Hidradenitis suppurativa (HS) is a complex, chronic skin disease characterised by painful inflammatory nodules, abscesses, dermal tunnels, sinus tracts and fistulae with a predilection for intertriginous skin. HS carries a substantial disease burden due to its prevalence, associated comorbidities and quality of life impacts and is associated with high healthcare resource utilisation. Clarity regarding the prevalence and pathogenesis of HS has led to improved therapies and more patients seeking care in both outpatient and acute care settings, including the emergency department. Emergency medicine providers play a critical role in HS diagnosis, management of acute flares and connection of HS patients with long-term dermatologic care, which can in turn help manage utilisation of acute care resources.

  • guideline
  • health service accessibility
  • Healthcare Disparities
  • pain management
  • dermatology

https://doi.org/10.1136/emermed-2024-213949

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Handling editor Richard Body

    • Contributors All authors made substantial contributions. DMK synthesised and wrote the content of the manuscript and served as the major editor during the revision process. FO synthesised and designed all the tables and figures of the manuscript and provided substantial contributions in the revisions of the text of the manuscript. HN proposed the project, advised on pertinent scope of the work and contributed to the editing of the text of the manuscript. GS provided the relevant perspective of an emergency medicine clinician and contributed to the drafting and editing of the manuscript. DMK and FO equally contributed to the final submission of the manuscript. DMK is the guarantor of the manuscript.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests HN has received grant support from AbbVie; consulting fees from 23andme, AbbVie, Aristea Therapeutics, Nimbus Therapeutics, Medscape, Sonoma Biotherapeutics, DAVA Oncology, Boehringer Ingelheim, Union Chimique Belge and Novartis; investigator fees from Pfizer; and holds shares in Radera. She is also an associate editor for JAMA Dermatology and a board member of the Hidradenitis Suppurativa Foundation.

    • Provenance and peer review Not commissioned; externally peer reviewed.